Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Athira Pharma Inc
(NQ:
ATHA
)
3.300
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Athira Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
Next >
Athira Pharma to Participate in Upcoming October Conferences
September 28, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
How The Same Treatments May Work For Multiple Neurodegenerative Diseases
September 21, 2023
Extensive research on NDDs has uncovered a different treatment pathway that's enabling some biotechnology firms to target more than one NDD with the same drug candidate.
Via
Talk Markets
Athira Pharma to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
September 19, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Second Quarter 2023 Financial Results and Pipeline and Business Updates
August 10, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents Phase 2 Clinical Data Correlating Improvements in Biomarkers of Neurodegeneration and Neuroinflammation with Improvements in Measures of Cognition and Function in Alzheimer’s Disease
July 17, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Presentations at the Alzheimer’s Association International Conference (AAIC) 2023
July 06, 2023
Three poster presentations to highlight clinical and preclinical data across Athira’s pipeline of neuroprotective therapeutic candidates
From
Athira Pharma, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
June 12, 2023
Via
Benzinga
Around $10M Bet On This Real Estate Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
June 07, 2023
The Dow Jones closed higher by around 10 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Athira Pharma to Participate in Upcoming June Conferences
May 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
May 22, 2023
Veteran biopharmaceutical executive brings over 30 years of financial, corporate strategy, transactional and business development experience
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports First Quarter 2023 Financial Results and Recent Pipeline and Business Updates
May 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Participate in Upcoming May Investor Conferences
May 08, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Presents New Clinical and Preclinical Data at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 25, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Upcoming Presentations at the American Academy of Neurology (AAN) 2023 Annual Meeting
April 11, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
$1.7M Bet On Glatfelter? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying
April 03, 2023
The Dow Jones closed higher by more than 400 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of Fosgonimeton for Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2023 International Conference
March 28, 2023
Data highlights potential neuroprotective, neurotrophic and anti-inflammatory effects of enhancing the HGF/MET system
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Reports Full Year 2022 Financial Results and Recent Pipeline and Business Updates
March 23, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Present at Upcoming Neuroscience Focused Investor Conferences
March 08, 2023
Company to highlight potential of its small molecule therapeutics that enhance the HGF/MET system to treat a variety of neurodegenerative diseases
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma, Inc. (NASDAQ:ATHA) Investor Alert: Investigation over Potential Wrongdoing
March 06, 2023
San Diego, CA -- (SBWIRE) -- 03/06/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Athira Pharma, Inc.
Via
SBWire
Athira Pharma to Present Data Supporting Therapeutic Potential of Enhancing HGF/MET Neurotrophic System at Upcoming Scientific Conferences
March 06, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Johnson & Johnson: Taking The Bull By The Horns?
February 21, 2023
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions.
Via
MarketBeat
Topics
Intellectual Property
Regulatory Compliance
Exposures
Intellectual Property
Legal
Regulatory
Athira Pharma Announces Publication in Journal of Alzheimer’s Disease Highlighting Need for Novel Alzheimer’s Disease Treatment Approaches and Potential of Enhancing HGF/MET Pathway
February 01, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma Announces Promotion of Kevin Church, Ph.D., to Chief Scientific Officer
January 31, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
NASDAQ:ATHA Shareholder Notice: Update in Lawsuit Against Athira Pharma, Inc.
January 18, 2023
San Diego, CA -- (SBWIRE) -- 01/18/2023 -- The Shareholders Foundation announced an update in the lawsuit that was filed on behalf of certain investors in Athira Pharma, Inc. (NASDAQ:ATHA).
Via
SBWire
Athira Pharma Provides 2023 Pipeline Outlook
January 05, 2023
From
Athira Pharma, Inc.
Via
GlobeNewswire
4 Penny Stocks Insiders Are Buying: Athira Pharma, Great Elm Group And More
January 03, 2023
US stocks recorded losses for 2022. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's...
Via
Benzinga
Athira Pharma Announces Publication of Fosgonimeton Preclinical Results in Neurotherapeutics
December 21, 2022
Data demonstrate fosgonimeton enhances the HGF/MET system, promoting neuroprotective, neurotrophic and procognitive effects in multiple cell and animal models
From
Athira Pharma, Inc.
Via
GlobeNewswire
Beachbody, Athira Pharma And This Penny Stock Insiders Are Aggressively Buying
December 07, 2022
The Dow Jones closed lower by nearly 350 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern...
Via
Benzinga
Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of ATH-1105 in ALS at the 33rd International Symposium on ALS/MND
December 05, 2022
From
Athira Pharma, Inc.
Via
GlobeNewswire
Athira Pharma to Host Virtual R&D Event on December 7, 2022, from 2:00 –3:30 pm Eastern time
December 01, 2022
Highlighting consistent preclinical and clinical data demonstrating the potential of HGF/MET as a neuroprotective and disease-modifying approach to treat neurodegenerative diseases
From
Athira Pharma, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.